Atherosclerosis
Volume 186, Issue 1 , Pages 1-11 , May 2006

LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention: A lesson from cholesterol turnover studies and others

  • Cesare R. Sirtori

      Affiliations

    • Corresponding Author InformationCorresponding authors. Tel.: +39 02 503 18303; fax: +39 02 503 18397.
    • ,
  • Remo Fumagalli

      Affiliations

    • Corresponding Author InformationCorresponding authors. Tel.: +39 02 503 18303; fax: +39 02 503 18397.

Received 29 June 2005 ,Revised 5 October 2005 ,Accepted 13 October 2005.

References 

  1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001–1009
  3. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  4. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440–1445
  5. Robins SJ, Collins D, Wittes JT, et al., VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585–91.
  6. Chapman MJ, Assmann G, Fruchart J-C, et al. on behalf of the European Consensus Panel on HDL-C Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004;20:1253–1268
  7. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER 2): a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517
  8. Chiesa G, Monteggia E, Marchesi M, et al. Recombinant apolipoprotein A-I Milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res. 2002;90:974–980
  9. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–2300
  10. Callahan AS. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr Atheroscler Rep. 2003;5:33–37
  11. Undas A, Celinska-Lowenhoff M, Kaczor M, Musial J. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost. 2004;91:1065–1077
  12. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  13. Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80mg and pravastatin 40mg in achieving the dual goals of low-density lipoprotein cholesterol <70mg/dl and C-reactive protein <2mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45:1644–1648
  14. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J. 2004;148(1 Suppl.):S19–S26
  15. Sampietro T, Bigazzi F, Dal Pino B, et al. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition?. Circulation. 2002;105:11–14
  16. Mostaza JM, Camino N, Gerique JG, et al. C-reactive protein levels and prevalence of chronic infections in subjects with hypoalphalipoproteinemia. Metabolism. 2005;54:33–37
  17. Wang TD, Chen WJ, Lin JW, et al. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis. 2003;170(2):315–323
  18. Chobanian AV, Hollander W. Body cholesterol metabolism in man. J Clin Invest. 1962;41:1732–1737
  19. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671
  20. Dollar AL, Kragel AH, Fernicola DJ, Waclawiw MA, Roberts WC. Composition of atherosclerosis plaques in coronary arteries in women <40 years of age with fatal coronary artery disease and implications for plaque reversibility. Am J Cardiol. 1991;67:1223–1227
  21. Kellner-Weibel G, Jerome WG, Small DM, et al. Effects of intracellular free cholesterol accumulation on macrophage viability. A model of foam cell death. Arterioscler Thromb Vasc Biol. 1998;18:423–431
  22. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part I. J Lipid Res. 2004;45:1583–1593
  23. Steinberg D. The cholesterol controversy is over. Why did it take so long?. Circulation. 1989;80:1070–1078
  24. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med. 1977;62:707–714
  25. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoprotein A-I and B, and HDL density subfractions. Circulation. 2001;104:1108–1113
  26. Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005;26:890–896
  27. van Lennep JE, Westerveld HT, van Lennep HW, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 2000;20:2408–2413
  28. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326–333
  29. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991;67:1185–1199
  30. Hausmann D, Johnson JA, Sudhir K, et al. Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: correlation with high density lipoproteins. J Am Coll Cardiol. 1996;27:1562–1570
  31. Baldassarre D, Amato M, Pustina L, et al. Increased carotid artery intima–media thickness in subjects with primary hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol. 2002;22:317–322
  32. O’Connell BJ, Genest J. High-density lipoproteins and endothelial function. Circulation. 2001;104:1978–1983
  33. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399–1402
  34. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944–2948
  35. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol. 2003;23:1724–1731
  36. Calabresi L, Gomaraschi M, Villa B, et al. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:656–661
  37. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142:95–104
  38. Goodman DS, Noble RP. Turnover of plasma cholesterol in man. J Clin Invest. 1968;47:231–241
  39. Jagannathan SN, Connor WE, Baker WH, Bhattacharyya AK. The turnover of cholesterol in human atherosclerotic arteries. J Clin Invest. 1974;54:366–377
  40. Miettinen TA. New insights into cholesterol dynamics. Arch Surg. 1978;113:45–49
  41. Stender S, Hjelms E. In vivo influx of free and esterified plasma cholesterol into human aortic tissue without atherosclerotic lesions. J Clin Invest. 1984;74:1871–1881
  42. Osono Y, Wolleett LA, Marotti KR, Melchior GW, Dietschy JM. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci USA. 1996;93:4114–4119
  43. Jolley CD, Wolleett LA, Turkey SD, Dietschy JA. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J Lipid Res. 1998;39:2143–2149
  44. Schmitz G, Langmann T. Structure, function and regulation of the ABC1 gene product. Curr Opin Lipidol. 2001;12:129–140
  45. Wang N, Tall AR. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:1178–1184
  46. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest. 2004;114:1343–1353
  47. Vaisman BL, Lambert G, Amar M, et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest. 2001;108:303–309
  48. Joyce C, Amar MJA, Lambert G, et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA. 2002;99:407–412
  49. Basso FP, Freeman L, Knapper CL, et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL-cholesterol concentrations. J Lipid Res. 2003;44:296–302
  50. Groen AK, Bloks VW, Bandsma RHJ, et al. Hepatobiliary cholesterol transport is not impaired in ABCA1-null mice lacking HDL. J Clin Invest. 2001;108:843–850
  51. Miller NE, Nestel PJ, Clifton-Bligh P. Relationships between plasma lipoprotein cholesterol concentrations and the pool size and metabolism of cholesterol in man. Atherosclerosis. 1976;23:535–547
  52. Nestel PJ, Miller ME. Cholesterol kinetics and faecal steroid excretion in subjects with primary hyperalphalipoproteinaemia. Atherosclerosis. 1980;36:127–134
  53. Blum CB, Dell RB, Palmer RH, et al. Relationship of the parameters of body cholesterol metabolism with plasma levels of HDL cholesterol and the major HDL apoproteins. J Lipid Res. 1985;26:1079–1088
  54. Miller NE. On the associations of body cholesterol pool size with age, HDL cholesterol and plasma total cholesterol concentration in humans. Atherosclerosis. 1987;163–172
  55. Dietschy JM. Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am J Clin Nutr. 1997;65:1581S–1589S
  56. Chiesa G, Michelagnoli S, Cassinotti M, et al. Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities. Metabolism. 1993;42:229–235
  57. Farkas MH, Swift LL, Hasty AH, Linton MF, Fazio S. The recycling of apolipoprotein E in primary cultures of mouse hepatocytes. Evidence for a physiologic connection to high density lipoprotein metabolism. J Biol Chem. 2003;278:9412–9417
  58. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:1732–1738
  59. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high density lipoproteins. Proc Natl Acad Sci USA. 2004;101:9774–9779
  60. Tall AR, Wang N, Mucksavage P. Is it the time to modify the reverse cholesterol transport model?. J Clin Invest. 2001;108:1273–1275
  61. Tall AR, Wang N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest. 2000;106:1205–1207
  62. Zhang Y, Zanotti I, Reilly MP, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661–663
  63. Brewer H, Remaley AT, Neufeld EB, Basso F, Joyce C. Regulation of plasma high density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscl Thromb Vasc Biol. 2004;24:17755–17760
  64. Ho K-J, Biss K, Taylor B. Serum cholesterol levels in US males. Arch Pathol. 1974;97:306–315
  65. Samuel P, Perl W. Long-term decay of serum cholesterol radioactivity: body cholesterol metabolism in normals and patients with hypercholesterolemia and atherosclerosis. J Clin Invest. 1970;49:346–357
  66. Feldman SA, Ho KJ, Lewis LA, Mikkelson B, Taylor CB. Lipid and cholesterol metabolism in Alaskan Arctic Eskimos. Arch Pathol Lab Med. 1972;94:42–58
  67. Moutafis CD, Simons LA, Myant NB, et al. The effect of cholestyramine on the faecal excretion of bile acids and neutral steroids in familial hypercholesterolaemia. Atherosclerosis. 1977;26:329–334
  68. Grundy SM, Bilheimer DW. Inhibition of 3-hydroxy-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance. Proc Natl Acad Sci USA. 1984;81:2538–2542
  69. Goldberg IJ, Holleran S, Ramakrishnan R, et al. Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. J Clin Invest. 1990;86:801–808
  70. Duane WC. Effects of lovastatin and dietary cholesterol on sterol homeostasis in healthy human subjects. J Clin Invest. 1993;92:911–918
  71. Reihner E, Rudling M, Stahlberg D, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med. 1990;323:224–228
  72. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol. 2003;91(4A):4B–8B
  73. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  74. Grundy SM, Ahrens EH, Salen G, et al. Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res. 1972;13:531–549
  75. Kudchodkar BJ, Sodhi HS, Horlick L, Mason DT. Mechanisms of hypolipidemic action of nicotinic acid. Clin Pharmacol Ther. 1978;24:354–373
  76. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005;25:1057–1064
  77. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 1999;100:594–598
  78. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs and stimulated reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586–1593
  79. Rodrigueza WV, Klimuk SK, Pritchard PH, Hope MJ. Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim Biophys Acta. 1998;1368:306–320
  80. Navab M, Anantharamaiah GM, Jama S, et al. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002;105:290–292
  81. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-β high density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109:3215–3220
  82. Navab M, Anantharamaiah GM, Reddy ST, et al. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2005;25:1932–1937
  83. Van Lenten BJ, Wagner AC, Navab M, et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation. 2004;110:3252–3258
  84. Li X, Chyu K-Y, Faria Neto JR, et al. Differential effects of apolipoprotein A-I mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation. 2004;110:1701–1705
  85. McDonald DL, Terry TL, Agellong LB, Nation PN, Francis GA. Administration of tyrosyl radical-oxidized HDL inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1583–1588
  86. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38
  87. Corti R, Fuster V, Fayad Z, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: 2 years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002;106:2884–2887
  88. Taylor A, Shaw LJ, Fayad Z, et al. Tracking atherosclerosis regression: a clinical tool in preventive cardiology. Atherosclerosis. 2005;180:1–10
  89. Birjmohun RS, Hutten BA, Kastelein JJP , et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185–197

PII: S0021-9150(05)00672-6

doi: 10.1016/j.atherosclerosis.2005.10.024

Atherosclerosis
Volume 186, Issue 1 , Pages 1-11 , May 2006

Article Tools

* Image Usage & Resolution